Anesthesia Updates

• IV Antihypertensives and Brain Perfusion: Friend or Foe?

  In this episode of NYSORA Updates in Anesthesiology, Dr. Hadzic breaks down a 2025 systematic review from the British Journal of Anaesthesia exploring how intravenous antihypertensives impact cerebral blood flow. Discover why nitroprusside and nitroglycerin demand extra caution, why nicardipine and labetalol remain safer bets, and how to avoid putting your patients at risk of cerebral hypoperfusion. Practical tips and takeaways you can apply today — don't miss it!Where else to find us: Web- ⁠⁠http://www.nysora.com⁠⁠ Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ Facebook- ⁠⁠facebook.com/nysora⁠⁠ Twitter- ⁠⁠x.com/nysora⁠⁠ TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ --------------------------------------------------------- ⁠⁠#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

  --------  

  6:27
• Transfuse or Not to Transfuse? Rethinking Hemoglobin Thresholds in TBI

  In this episode, Dr. Hadzic breaks down the latest meta-analysis on transfusion strategies in traumatic brain injury patients. Are we under-transfusing and compromising brain recovery? Evidence now points to a liberal transfusion strategy with a 9 g/dL threshold improving neurologic outcomes, without increasing mortality. But watch out: ARDS risk rises. Tune in to hear why current guidelines may need a serious update and how this could shift your ICU practice.Where else to find us: Web- ⁠⁠http://www.nysora.com⁠⁠ Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ Facebook- ⁠⁠facebook.com/nysora⁠⁠ Twitter- ⁠⁠x.com/nysora⁠⁠ TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ --------------------------------------------------------- ⁠⁠#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

  --------  

  7:41
• Sugammadex in Crisis: Can It Save a CICV Scenario?

  In this episode of NYSORA Podcast: Updates in Anesthesiology, Dr. Hadzic breaks down a 2025 systematic review by Dr. Nancy Abou Nafeh and colleagues, exploring whether sugammadex can truly rescue patients in 'cannot intubate, cannot ventilate' (CICV) emergencies. With a 75% success rate in reported cases but crucial limitations in timing, dosing, and airway obstruction, we explore the real-world utility of this rapid-reversal agent—and why it's not a magic bullet. Tune in for key clinical takeaways that may change how you prepare for your next high-risk airway.Where else to find us: Web- ⁠⁠http://www.nysora.com⁠⁠ Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ Facebook- ⁠⁠facebook.com/nysora⁠⁠ Twitter- ⁠⁠x.com/nysora⁠⁠ TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ --------------------------------------------------------- ⁠⁠#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

  --------  

  9:16
• HPI in the OR: Prediction Without Prevention?

  In this episode of Updates in Anesthesiology, Dr. Hadzic unpacks a major 2025 multicenter trial by Dr. Javier Ripollés-Melchor and colleagues, exploring whether the Hypotension Prediction Index (HPI) can actually reduce postoperative acute kidney injury (AKI) in abdominal surgery. Despite HPI’s promise in predicting intraoperative hypotension, the trial found no reduction in AKI or overall complications compared to standard care. We break down what this means for your practice, how vasopressor choice might matter more than prediction tools, and why clinical judgment still reigns supreme in the OR. Stay tuned for the key takeaways and what to do with that HPI alert next time it flashes on your monitor.Where else to find us: Web- ⁠⁠http://www.nysora.com⁠⁠ Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ Facebook- ⁠⁠facebook.com/nysora⁠⁠ Twitter- ⁠⁠x.com/nysora⁠⁠ TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ --------------------------------------------------------- ⁠⁠#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

  --------  

  7:33
• Neuraxial Anesthesia Isn't Dead: Reclaiming Its Role After REGAIN

  In this episode of Updates in Anesthesiology, Dr. Hadzic explores the ongoing role of neuraxial anesthesia in hip fracture surgery following the widely publicized REGAIN and RAGA trials. Despite claims of equivalence between general and neuraxial techniques, Dr. Alexander Stone and colleagues argue that these trials may have lacked the statistical power and mechanistic clarity to support such a conclusion. We break down the clinical benefits of neuraxial anesthesia—like reduced pulmonary complications, VTE risk, and opioid use—and discuss why abandoning it as a default choice could be a misstep. Tune in for practical, evidence-based insights that help anesthesiologists personalize care and keep patient outcomes front and center.Where else to find us: Web- ⁠⁠http://www.nysora.com⁠⁠ Instagram- ⁠⁠instagram.com/nysora.inc/ ⁠⁠LinkedIN- ⁠⁠linkedin.com/company/nysora-inc/⁠⁠ Facebook- ⁠⁠facebook.com/nysora⁠⁠ Twitter- ⁠⁠x.com/nysora⁠⁠ TikTok- ⁠⁠tiktok.com/@nysora_inc⁠⁠ --------------------------------------------------------- ⁠⁠#nysora⁠⁠ ⁠⁠#regionalanesthesia⁠⁠ ⁠⁠#anesthesia⁠⁠Disclaimer: Medicine is an ever-changing science. As new research and clinical experience broaden, changes in treatment and drug therapy are required. The authors and publishers have checked with sources believed to be reliable in efforts to provide accurate information within the available or accepted standards of care. However, given the possibility of human error or changes in medical practice, neither the authors nor the publisher, nor any other party involved in the preparation of this platform warrants that the information contained herein is in every aspect accurate or complete, and they disclaim all responsibility for any errors or omissions for the results obtained from the use of the information contained in this work. Readers are advised to confirm the information contained herein with other sources. For example, readers are advised to check the product information of each drug mentioned, and that any information contained on NYSORA's Podcast is accurate.

  --------  

  8:33

Mais podcasts de Saúde e fitness

Podcasts em tendência em Saúde e fitness

Sobre Anesthesia Updates